Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

BACKGROUND: Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects. This post hoc analysis investigated the association between major adverse cardiovascular events (MACE) and baseline kidney...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossing, Peter, Bain, Stephen C., Bosch-Traberg, Heidrun, Sokareva, Ekaterina, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463803/
https://www.ncbi.nlm.nih.gov/pubmed/37620807
http://dx.doi.org/10.1186/s12933-023-01949-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463803/
https://www.ncbi.nlm.nih.gov/pubmed/37620807
http://dx.doi.org/10.1186/s12933-023-01949-7

Ejemplares similares